Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Long-Term Investments (2016 - 2025)

Regenxbio has reported Long-Term Investments over the past 12 years, most recently at $10.8 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $10.8 million for Q4 2025, up 5.95% from a year ago — trailing twelve months through Dec 2025 was $10.8 million (up 5.95% YoY), and the annual figure for FY2025 was $10.8 million, up 5.95%.
  • Long-Term Investments for Q4 2025 was $10.8 million at Regenxbio, down from $27.8 million in the prior quarter.
  • Over the last five years, Long-Term Investments for RGNX hit a ceiling of $391.9 million in Q4 2021 and a floor of $4.9 million in Q1 2025.
  • Median Long-Term Investments over the past 5 years was $79.0 million (2023), compared with a mean of $131.9 million.
  • Biggest five-year swings in Long-Term Investments: surged 737.25% in 2021 and later crashed 88.38% in 2025.
  • Regenxbio's Long-Term Investments stood at $391.9 million in 2021, then crashed by 48.82% to $200.6 million in 2022, then plummeted by 80.62% to $38.9 million in 2023, then tumbled by 73.81% to $10.2 million in 2024, then rose by 5.95% to $10.8 million in 2025.
  • The last three reported values for Long-Term Investments were $10.8 million (Q4 2025), $27.8 million (Q3 2025), and $40.3 million (Q2 2025) per Business Quant data.